Increased G6P and F26BP activate transcriptional activity of ChREBP/Mlx in hepatocytes and, through this, increased expression of glycolytic, gluconeogenic, and lipogenic genes, which contributes to hepatic steatosis and insulin resistance—including increased expression and activity of ChREBPβ [73,77,82]. This evidence concerns the gene MLXIPL and fatty liver disease.